CA2566199C - Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes - Google Patents
Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes Download PDFInfo
- Publication number
- CA2566199C CA2566199C CA2566199A CA2566199A CA2566199C CA 2566199 C CA2566199 C CA 2566199C CA 2566199 A CA2566199 A CA 2566199A CA 2566199 A CA2566199 A CA 2566199A CA 2566199 C CA2566199 C CA 2566199C
- Authority
- CA
- Canada
- Prior art keywords
- microspheres
- composition
- oligonucleotides
- microns
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 91
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title claims abstract description 13
- 210000004443 dendritic cell Anatomy 0.000 title claims description 18
- 230000001363 autoimmune Effects 0.000 title claims description 13
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 53
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000002245 particle Substances 0.000 claims abstract description 29
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims abstract description 22
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims abstract description 22
- 101150013553 CD40 gene Proteins 0.000 claims abstract description 20
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims description 41
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 21
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 21
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 241000699670 Mus sp. Species 0.000 claims description 12
- 230000006378 damage Effects 0.000 claims description 12
- 206010012601 diabetes mellitus Diseases 0.000 claims description 12
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 9
- 230000014509 gene expression Effects 0.000 claims description 8
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 4
- 239000007929 subcutaneous injection Substances 0.000 claims description 4
- 239000007972 injectable composition Substances 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 17
- 229920000642 polymer Polymers 0.000 description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 11
- 239000011859 microparticle Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 7
- 108010005774 beta-Galactosidase Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 7
- 241001427367 Gardena Species 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 102000005936 beta-Galactosidase Human genes 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- -1 phase separation Chemical class 0.000 description 4
- 108010055896 polyornithine Proteins 0.000 description 4
- 238000001878 scanning electron micrograph Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000004046 hyporesponsiveness Effects 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Abstract
This application refers to microspheres comprising oligonucleotides for treatment of type 1 diabetes, said oligonucleotides comprise between about 30 weight percent and about 100 weight percent of the microspheres, based on the total weight of the microspheres, said microspheres having an average particle size of not greater than about 50 microns. The oligonucleotides are targeted to bind to primary transcripts selected from the group consisting of CD40, CD80 and CD86 primary transcripts, and combinations thereof.
Description
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
NOTE: For additional volumes please contact the Canadian Patent Office.
DELIVERY OF AS-OLIGONUCLEOTIDE MICROSPHERES TO INDUCE
DENDRITIC CELL TOLERANCE FOR THE TREATMENT
Description Cross References to Related Application [0001] Patent Application Nos. 7,815,941 and 7,884,085.
Background of the Invention Field of the Invention [0002] The present invention generally relates to microsphere delivery of AS-oligonucleotides in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. More particularly, the invention relates to drug delivery technology by way of microspheres that are fabricated using totally aqueous conditions, which microspheres incorporate antisense (AS) oligonucleotides. These microspheres are used for an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ.
Background of the Invention [0003] Microparticles, microspheres, and microcapsules are solid or semi-solid particles having a diameter of less than one millimeter, more preferably less than 100 microns, which can be formed of a variety of materials, including synthetic polymers, proteins, and polysaccharides.
Microspheres have been used in many different applications, primarily separations, diagnostics, and drug delivery.
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
NOTE: For additional volumes please contact the Canadian Patent Office.
DELIVERY OF AS-OLIGONUCLEOTIDE MICROSPHERES TO INDUCE
DENDRITIC CELL TOLERANCE FOR THE TREATMENT
Description Cross References to Related Application [0001] Patent Application Nos. 7,815,941 and 7,884,085.
Background of the Invention Field of the Invention [0002] The present invention generally relates to microsphere delivery of AS-oligonucleotides in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. More particularly, the invention relates to drug delivery technology by way of microspheres that are fabricated using totally aqueous conditions, which microspheres incorporate antisense (AS) oligonucleotides. These microspheres are used for an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ.
Background of the Invention [0003] Microparticles, microspheres, and microcapsules are solid or semi-solid particles having a diameter of less than one millimeter, more preferably less than 100 microns, which can be formed of a variety of materials, including synthetic polymers, proteins, and polysaccharides.
Microspheres have been used in many different applications, primarily separations, diagnostics, and drug delivery.
[0004] A number of different techniques can be used to make these microspheres from synthetic polymers, natural polymers, proteins and polysaccharides, including phase separation, solvent evaporation, emulsification, and spray drying.
Generally the polymers form the supporting structure of these microspheres, and the drug of interest is incorporated into the polymer structure. Exemplary polymers used for the formation of microspheres include homopolymers and copolymers of lactic acid and glycolic acid (PLGA) as described in U.S.
Pat. No. 5,213,812 to Ruiz, U.S. Pat. No. 5,417,986 to Reid et al., U.S. Pat. No. 4,530,840 to Tice et al., U.S. Pat. No.
4,897,268 to Tice et al., U.S. Pat. No. 5,075,109 to Tice et al., U.S. Pat. No. 5,102,872 to Singh et al., U.S. Pat. No.
Generally the polymers form the supporting structure of these microspheres, and the drug of interest is incorporated into the polymer structure. Exemplary polymers used for the formation of microspheres include homopolymers and copolymers of lactic acid and glycolic acid (PLGA) as described in U.S.
Pat. No. 5,213,812 to Ruiz, U.S. Pat. No. 5,417,986 to Reid et al., U.S. Pat. No. 4,530,840 to Tice et al., U.S. Pat. No.
4,897,268 to Tice et al., U.S. Pat. No. 5,075,109 to Tice et al., U.S. Pat. No. 5,102,872 to Singh et al., U.S. Pat. No.
5,384,133 to Boyes et al., U.S. Pat. No. 5,360,610 to Tice et al., and European Patent Application Publication Number 248,531 to Southern Research Institute; block copolymers such as tetronic 908 and poloxamer 407 as described in U.S. Pat.
No. 4,904,479 to Ilium; and polyphosphazenes as described in U.S. Pat. No. 5,149,543 to Cohen et al. Microspheres produced using polymers such as these exhibit a poor loading efficiency and are often only able to incorporate a small percentage of the drug of interest into the polymer structure. Therefore, substantial quantities of microspheres often must be administered to achieve a therapeutic effect.
[0005] Spherical beads or particles have been commercially available as a tool for biochemists for many years. For example, antibodies conjugated to beads create relatively large particles specific for particular ligands. The large antibody-coated particles are routinely used to crosslink receptors on the surface of a cell for cellular activation, are bound to a solid phase for immunoaffinity purification, and may be used to deliver a therapeutic agent that is slowly released over time, using tissue or tumor-specific antibodies conjugated to the particles to target the agent to the desired site.
No. 4,904,479 to Ilium; and polyphosphazenes as described in U.S. Pat. No. 5,149,543 to Cohen et al. Microspheres produced using polymers such as these exhibit a poor loading efficiency and are often only able to incorporate a small percentage of the drug of interest into the polymer structure. Therefore, substantial quantities of microspheres often must be administered to achieve a therapeutic effect.
[0005] Spherical beads or particles have been commercially available as a tool for biochemists for many years. For example, antibodies conjugated to beads create relatively large particles specific for particular ligands. The large antibody-coated particles are routinely used to crosslink receptors on the surface of a cell for cellular activation, are bound to a solid phase for immunoaffinity purification, and may be used to deliver a therapeutic agent that is slowly released over time, using tissue or tumor-specific antibodies conjugated to the particles to target the agent to the desired site.
[0006] One disadvantage of the microparticles or beads currently available is that they are difficult and expensive to produce. Microparticles produced by these known methods have a wide particle size distribution, often lack uniformity, and fail to exhibit long term release kinetics when the concentration of active ingredients is high. Furthermore, the polymers used in these known methods are dissolved in organic solvents in order to form the microparticles. They must therefore be produced in special facilities designed to handle organic solvents. These organic solvents could denature proteins or peptides contained in the microparticles. Residual organic solvents could be toxic when administered to humans or animals.
[0007] In addition, the available microparticles are rarely of a size sufficiently small to fit through the aperture of the size of needle commonly used to administer therapeutics or to be useful for administration by inhalation. For example, microparticles prepared using polylactic glycolic acid (PLGA) are large and have a tendency to aggregate. A size selection step, resulting in product loss, is necessary to remove particles too large for injection. PLGA particles that are of a suitable size for injection must be administered through a large gauge needle to accommodate the large particle size, often causing discomfort for the patient.
[0008] Generally, many currently available microparticles are activated to release their contents in aqueous media and therefore must be lyophilized to prevent premature release.
In addition, particles such as those prepared using the PLGA
system exhibit release kinetics based on both erosion and diffusion. In this type of system, an initial burst or rapid release of drug is observed. This burst effect can result in . unwanted side effects in patients to whom the particles have been administered.
In addition, particles such as those prepared using the PLGA
system exhibit release kinetics based on both erosion and diffusion. In this type of system, an initial burst or rapid release of drug is observed. This burst effect can result in . unwanted side effects in patients to whom the particles have been administered.
[0009] Microparticles prepared using lipids to encapsulate target drugs are known. For example, lipids arranged in bilayer membranes surrounding multiple aqueous compartments to form particles may be used to encapsulate water soluble drugs for subsequent delivery as described in U.S. Pat. No.
5,422,120 to Sinil Kim. These particles are generally greater than 10 microns in size and are designed for intra articular, intrathecal, subcutaneous and epidural administration.
Alternatively, liposomes have been used for intravenous delivery of small molecules. Liposomes are spherical particles composed of a single or multiple phospholipid and cholesterol bilayers. Liposomes are 30 microns or greater in size and may carry a variety of water-soluble or lipid-soluble drugs. Liposome technology has been hindered by problems including purity of lipid components, possible toxicity, vesicle heterogeneity and stability, excessive uptake and manufacturing or shelf-life difficulties.
5,422,120 to Sinil Kim. These particles are generally greater than 10 microns in size and are designed for intra articular, intrathecal, subcutaneous and epidural administration.
Alternatively, liposomes have been used for intravenous delivery of small molecules. Liposomes are spherical particles composed of a single or multiple phospholipid and cholesterol bilayers. Liposomes are 30 microns or greater in size and may carry a variety of water-soluble or lipid-soluble drugs. Liposome technology has been hindered by problems including purity of lipid components, possible toxicity, vesicle heterogeneity and stability, excessive uptake and manufacturing or shelf-life difficulties.
[00010] An objective for the medical community is the delivery of nucleic acids to the cells in an animal for diabetes treatment. For example, nucleic acids can be delivered to cells in culture (in vitro) relatively efficiently, but nucleases result in a high rate of nucleic acid degradation when nucleic acid is delivered to animals (in vivo).
[00011] In addition to protecting nucleic acid from nuclease digestion, a nucleic acid delivery vehicle must exhibit low toxicity, must be efficiently taken up by cells and have a well-defined, readily manufactured formulation. As shown in clinical trials, viral vectors for delivery can result in a severely adverse, even fatal, immune response in vivo. In addition, this method has the potential to have mutagenic effects in vivo. Delivery by enclosing nucleic acid in lipid complexes of different formulations (such as liposomes or cationic lipid complexes) has been generally ineffective in vivo and can have toxic effects. Complexes of nucleic acids with various polymers or with peptides have shown inconsistent results and the toxicity of these formulations has not yet been resolved. Nucleic acids also have been encapsulated in polymer matrices for delivery, but in these cases the particles have a wide size range and the effectiveness for therapeutic applications has not yet been demonstrated.
[00012] Therefore, there is a need for addressing nucleic acids delivery issues, and there is an on-going need for development of microspheres and to new methods for making microspheres. Details regarding microspheres are found in US
Patents No. 6,458,387 to Scott et al., No. 6,268,053, No.
6,090,925, No. 5,981,719 and No. 5,599,719 to Woiszwillo et al., and No. 5,578,709 to Woiszwillo.
Summary of the Invention [00013] In accordance with the present invention, DNA to be delivered to dendritic cells is delivered as microspheres. It is believed that such a delivery approach prevents access of the nucleases to the nucleic acids within the microsphere.
Microsphere delivery of AS-oligonucleotides is carried out in order to induce dendritic cell tolerance, particularly in the NOD mouse model. The microspheres are fabricated using aqueous conditions, which microspheres incorporate antisense (AS) oligonucleotides. These microspheres are used to inhibit gene expression and to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ.
Patents No. 6,458,387 to Scott et al., No. 6,268,053, No.
6,090,925, No. 5,981,719 and No. 5,599,719 to Woiszwillo et al., and No. 5,578,709 to Woiszwillo.
Summary of the Invention [00013] In accordance with the present invention, DNA to be delivered to dendritic cells is delivered as microspheres. It is believed that such a delivery approach prevents access of the nucleases to the nucleic acids within the microsphere.
Microsphere delivery of AS-oligonucleotides is carried out in order to induce dendritic cell tolerance, particularly in the NOD mouse model. The microspheres are fabricated using aqueous conditions, which microspheres incorporate antisense (AS) oligonucleotides. These microspheres are used to inhibit gene expression and to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ.
[00014] In a preferred aspect of the invention, three AS-oligonucleotides targeted to the CD40, CD80 and CD86 primary transcripts are synthesized, and an aqueous solution of the oligonucleotide mixture is prepared and combined with a polymer solution. After processing, microspheres containing the oligonucleotides are provided, and these are delivered to the NOD mice.
[00014a] According to another aspect, there is provided a composition comprising microspheres, wherein said microspheres contain a first antisense oligonucleotide that targets CD40 primary transcript, a second antisense oligonucleotide that targets CD80 primary transcript, and a third antisense oligonucleotide that targets CD86 primary transcript, wherein each of said first, second and third oligonucleotides reduces or suppresses in vivo expression of CD40, CD80 and CD86 respectively, and wherein said oligonucleotides comprise between 30 weight percent and 100 weight percent of the microspheres, based on the total weight of the microspheres, said microspheres having an average particle size of not greater than 50 microns.
[00014b] According to a further aspect, there is provided a composition comprising microspheres wherein the microspheres comprise oligonucleotides targeted to bind primary transcripts selected from the group consisting of CD40, CD80, and CD86 primary transcripts and combinations thereof, wherein the oligonucleotides reduce or suppress the expression of 0D40, CD80 and/or CD86, and wherein the oligonucleotides comprise greater than 30 weight percent of the microspheres based on total weight of the microspheres.
[00014c] According to another aspect, there is provided an injectable composition for the treatment of type 1 diabetes comprising microspheres, said microspheres comprising a first antisense oligonucleotide that targets CD40 primary transcript, a second antisense oligonucleotide that targets CD80 primary transcript, and a third antisense oligonucleotide that targets CD86 primary transcript, wherein each of said first, second and third antisense oligonucleotides reduces or suppresses the expression of 0D40, CD80 and CD86 respectively, wherein said first, second and third antisense oligonucleotides comprise greater than 30% by weight of said microspheres.
[00014a] According to another aspect, there is provided a composition comprising microspheres, wherein said microspheres contain a first antisense oligonucleotide that targets CD40 primary transcript, a second antisense oligonucleotide that targets CD80 primary transcript, and a third antisense oligonucleotide that targets CD86 primary transcript, wherein each of said first, second and third oligonucleotides reduces or suppresses in vivo expression of CD40, CD80 and CD86 respectively, and wherein said oligonucleotides comprise between 30 weight percent and 100 weight percent of the microspheres, based on the total weight of the microspheres, said microspheres having an average particle size of not greater than 50 microns.
[00014b] According to a further aspect, there is provided a composition comprising microspheres wherein the microspheres comprise oligonucleotides targeted to bind primary transcripts selected from the group consisting of CD40, CD80, and CD86 primary transcripts and combinations thereof, wherein the oligonucleotides reduce or suppress the expression of 0D40, CD80 and/or CD86, and wherein the oligonucleotides comprise greater than 30 weight percent of the microspheres based on total weight of the microspheres.
[00014c] According to another aspect, there is provided an injectable composition for the treatment of type 1 diabetes comprising microspheres, said microspheres comprising a first antisense oligonucleotide that targets CD40 primary transcript, a second antisense oligonucleotide that targets CD80 primary transcript, and a third antisense oligonucleotide that targets CD86 primary transcript, wherein each of said first, second and third antisense oligonucleotides reduces or suppresses the expression of 0D40, CD80 and CD86 respectively, wherein said first, second and third antisense oligonucleotides comprise greater than 30% by weight of said microspheres.
[00015] These and other aspects, features and advantages of the present invention, including the various combinations, will be apparent from and clearly understood through a consideration of the following detailed description.
Brief Description of the Drawings [00016] In the course of this description, reference will be made to the attached drawings, wherein:
Brief Description of the Drawings [00016] In the course of this description, reference will be made to the attached drawings, wherein:
[00017] Fig. 1 is a schematic illustration of the role of dendritic cells in the autoimmune destruction of pancreatic insulin-producing beta-cells in Type 1 diabetes;
[00018] Fig. 2 is a diagram of the Beta-Galactosidase gene-containing plasmid vector;
[00019] Fig. 3 shows photomicrographs providing evidence for transfection of NIH 3T3 fibroblast cells with the plasmid DNA microspheres;
[00020] Fig. 4 is a photomicrograph of agarose electrophoresis gel of naked plasmid DNA and of two plasmid DNA microsphere formulations according to the invention, each after exposure to DNAase;
[00021] Fig. 5 is a bar graph of Beta-Galactosidase activity in four different plasmid DNA applications.
- 6a -[00022] Fig. 6 is a scanning electron migrograph of microspheres of AS-oligonucleotides and poly-L---lysine polycation;
- 6a -[00022] Fig. 6 is a scanning electron migrograph of microspheres of AS-oligonucleotides and poly-L---lysine polycation;
[00023] Fig. 7 is a scanning electron micrograph of microspheres of AS-oligonucleotides and poly-L-ornithine polycation; and [00024] Fig. 8 is a plot summarizing diabetes incidence in three groups of NOD mice treated with the microspheres and according to other procedures for delivery of the three primary transcripts.
Description of the Preferred Embodiments [00025] As required, detailed embodiments of the present invention are disclosed herein; however, it is to be understood that the disclosed embodiments are merely exemplary of the invention, which may be embodied in various forms.
Therefore, specific details disclosed herein are not to be interpreted as limiting, but merely as a basis for the claims and as a representative basis for teaching one skilled in the art to variously employ the present invention in virtually any appropriate manner.
Description of the Preferred Embodiments [00025] As required, detailed embodiments of the present invention are disclosed herein; however, it is to be understood that the disclosed embodiments are merely exemplary of the invention, which may be embodied in various forms.
Therefore, specific details disclosed herein are not to be interpreted as limiting, but merely as a basis for the claims and as a representative basis for teaching one skilled in the art to variously employ the present invention in virtually any appropriate manner.
[00026] The preferred embodiment prevents autoimmune insulin-dependent diabetes by formulating and injecting antisense (AS)-oligonucleotide microspheres described herein targeting the primary transcripts of CD40, CD80 and CD86.
These oligonucleotides are designed to induce immune tolerance in an attempt to prevent destruction of the insulin producing beta cells in the NOD mouse model. The events leading to the destruction of these beta cells is illustrated in Fig. 1.
This illustrates how Type 1 diabetes is manifested by the autoimmune destruction of the pancreatic insulin-producing beta cells in the NOD mouse, as well as in humans. At the time of clinical onset, humans have 10-20% residual beta cell mass. Sparing of this residual mass can result in remaining insulin levels which are adequate to regulate glucose levels.
The microparticles of the invention are provided to interfere with the autoimmune destruction of the beta cells which is illustrated in Fig. 1.
These oligonucleotides are designed to induce immune tolerance in an attempt to prevent destruction of the insulin producing beta cells in the NOD mouse model. The events leading to the destruction of these beta cells is illustrated in Fig. 1.
This illustrates how Type 1 diabetes is manifested by the autoimmune destruction of the pancreatic insulin-producing beta cells in the NOD mouse, as well as in humans. At the time of clinical onset, humans have 10-20% residual beta cell mass. Sparing of this residual mass can result in remaining insulin levels which are adequate to regulate glucose levels.
The microparticles of the invention are provided to interfere with the autoimmune destruction of the beta cells which is illustrated in Fig. 1.
[00027] It will be appreciated that dendritic cells (DC) can be activated to be potent antigen presenting cells found in all tissues and which are highly concentrated under the skin.
These antigen presenting dendritic cells function as triggers of the immune response through the activation of T-cells, particularly in lymph nodes.
These antigen presenting dendritic cells function as triggers of the immune response through the activation of T-cells, particularly in lymph nodes.
[00028] Fig. 2 is a drawing of a plasmid vector containing the Beta-galactosidase gene that can be used to transfect NIH
3T3 fibroblast cells. In vitro evidence for the transfection of NIH 3T3 fibroblast cells with the plasmid DNA microspheres is shown in Fig. 3 by the cells which stain blue in color in response to the addition of the Beta-Galactosidase x-gal (5-bromo-4-chloro-3-indolyl-beta-galactopyranoside) substrate.
3T3 fibroblast cells. In vitro evidence for the transfection of NIH 3T3 fibroblast cells with the plasmid DNA microspheres is shown in Fig. 3 by the cells which stain blue in color in response to the addition of the Beta-Galactosidase x-gal (5-bromo-4-chloro-3-indolyl-beta-galactopyranoside) substrate.
[00029] Fig. 4 illustrates the ability of microspheres to protect DNA in solution. This is an agarose electrophoresis gel showing nuclease protection imparted by microspheres of plasmid DNA produced generally as noted herein. In the Plasmid samples 1, 2 and 3, naked plasmid DNA was exposed to DNAse, with the smears indicating plasmid DNA degradation at each of the three levels of DNAase application. In the Particle 1 and Particle 2 samples, plasmid DNA microsphere formulations were exposed to DNAase. The lack of smearing indicates the microsphere formulations show shielding of the plasmid DNA from degradation.
[00030] Fig. 5 reports on Beta-Galactosidase activity in four different plasmid DNA applications. The naked plasmid DNA application showed very low levels. Somewhat greater levels are indicated for plasmid DNA cationic lipid complex application using lipofectamine, a commercial cationic lipid, as the delivery vehicle. Substantially greater activity is shown for two pDNA microspheres, with Microspheres 1 corresponding to Particle 1 of Fig. 4, and Microspheres 2 corresponding to Particle 2 of Fig. 4.
[00031] In making the microspheres that are used for autoimmune treatment of diabetes in mice, three AS-oligonucleotides are dissolved in aqueous solution and combined with water soluble polymer(s) and a polycation. The solution typically is incubated at about 60-70 C, cooled to about 23 C, and the excess polymer is removed. Microspheres are formed which are believed to contain the three AS-oligonucleotides having the following sequences, wherein an asterisk indicates thioation:
Seq ID 1: CD 40-AS: 5'C*AC* AG*C C*GA* GG*C* AA*A
GA*C* AC*C A*T*G C*AG* GG*C* A-3' Seq ID 2: CD80-AS: 5r-G*GG* AA*A G*CC* AG*G A*AT* CT*A
G*AG* CC*A A*TG G*A-3' Seq ID 3: CD86-AS: 5'-T*GG* GT*G C*TT* CC*G T*AA*
GT*T C*TG* GA*A C*AC* G*T*C-3' [00032] More particularly, the nucleic acids typically comprise between about 30 and about 100 weight percent of the microspheres and have an average particle size of not greater than about 50 microns. Typically, they are prepared as follows. An aqueous solution of the oligonucleotide mixture is prepared by combining aliquots from three oligonucleotide solutions, each solution containing one of these three types.
A solution containing the three types of oligonucleotides is prepared. The solutions preferably contain about 10 mg/ml oligonucleotide. These are combined with aliquots of a 10 mg/ml stock solution of polycation solution at volumetric ratios of polycation:oligonucleotide of from about 1:1 to about 4:1. Polymer solutions of polyvinyl pyrrolidone and/or of polyethylene glycol are prepared and combined with the other solutions. Heating, cooling, centrifuging and washing multiple times provide an aqueous suspension which typically is frozen and lyophilized to form a dry powder of microspheres comprising oligonucleotide and polycation.
Seq ID 1: CD 40-AS: 5'C*AC* AG*C C*GA* GG*C* AA*A
GA*C* AC*C A*T*G C*AG* GG*C* A-3' Seq ID 2: CD80-AS: 5r-G*GG* AA*A G*CC* AG*G A*AT* CT*A
G*AG* CC*A A*TG G*A-3' Seq ID 3: CD86-AS: 5'-T*GG* GT*G C*TT* CC*G T*AA*
GT*T C*TG* GA*A C*AC* G*T*C-3' [00032] More particularly, the nucleic acids typically comprise between about 30 and about 100 weight percent of the microspheres and have an average particle size of not greater than about 50 microns. Typically, they are prepared as follows. An aqueous solution of the oligonucleotide mixture is prepared by combining aliquots from three oligonucleotide solutions, each solution containing one of these three types.
A solution containing the three types of oligonucleotides is prepared. The solutions preferably contain about 10 mg/ml oligonucleotide. These are combined with aliquots of a 10 mg/ml stock solution of polycation solution at volumetric ratios of polycation:oligonucleotide of from about 1:1 to about 4:1. Polymer solutions of polyvinyl pyrrolidone and/or of polyethylene glycol are prepared and combined with the other solutions. Heating, cooling, centrifuging and washing multiple times provide an aqueous suspension which typically is frozen and lyophilized to form a dry powder of microspheres comprising oligonucleotide and polycation.
[00033] Microspheres according to the invention are a viable non-viral delivery tool for plasmid DNA and antisense oligonucleotides and other nucleic acids. They allow for in vitro delivery of Beta-Galactosidase plasmid DNA in 3T3 fibroblast cells. The microspheres protect plasmid DNA from nuclease activity. High levels of Beta-Galactosidase activity are expressed following transfection with the microsphere formulations.
[00034] Microspheres containing the antisense oligonucleotides of interest down-regulate surface cell antigens CD40, 0D80 and CD86, known to be critical in the activation of the autoimmune reaction that results in destruction of insulin-producing beta cells of the pancreas.
This can be accomplished by subcutaneous injection to dendritic cells located under the skin. NOD mice studies demonstrate effective prevention of the autoimmune destruction of beta cells. The DNA and oligonucleotide microspheres are effective transfection vehicles in vitro and in vivo.
Dendritic cells appear to take up the oligonucleotide microspheres and suppress the expression of surface cell antigens CD40, CD80 and CD86. The anitsense oligonucleotide microspheres effectively prevent diabetes development in the NOD mouse.
This can be accomplished by subcutaneous injection to dendritic cells located under the skin. NOD mice studies demonstrate effective prevention of the autoimmune destruction of beta cells. The DNA and oligonucleotide microspheres are effective transfection vehicles in vitro and in vivo.
Dendritic cells appear to take up the oligonucleotide microspheres and suppress the expression of surface cell antigens CD40, CD80 and CD86. The anitsense oligonucleotide microspheres effectively prevent diabetes development in the NOD mouse.
[00035] The following Examples illustrate certain features and advantages of the invention in order to further illustrate the invention. The Examples are not to be considered limiting or otherwise restrictive of the invention.
[00036] Three AS-oligonucleotides targeted to the CD40, CD80 and CD86 primary transcripts were synthesized by the DNA
synthesis facility at University of Pittsburgh (Pittsburgh, PA). The AS-oligonucleotides sequences are:
Seq ID 1: CD 40-AS: 5'C*AC* AG*C C*GA* GG*C* AA*A
GA*C* AC*C A*T*G C*AG* GG*C* A-3' Seq ID 2: CD80-AS: 5'-G*GG* AA*A G*CC* AG*G A*AT* CT*A
G*AG* CC*A A*TG G*A-3' Seq ID 3: CD86-AS: 5'-T*GG* GT*G C*TT* CC*G T*AA*
GT*T C*TG* GA*A C*AC* G*T*C-3' [00037] An aqueous solution of the oligonucleotide mixture was prepared by combining aliquots of three oligonucleotide solutions, each of which contained one type of oligonucleotide, to form a 10[mg/m1] solution of the three types of oligonucleotides. 10 [mg/ml] poly-L-lysine.HBr in diH20 (poly-L-lysine.HBr up to 50,000 by Bachem, King of Prussia, PA) was prepared. Poly-L-lysine.HBr was added to the oligonucleotides solution at a volumetric ratio of 1:1. The mixture was vortexed gently. A 25% polymer solution containing 12.5% PVP (polyvinyl pyrrolidone, 40,000 Daltons, Spectrum Chemicals, Gardena, CA) and 12.5% PEG (polyethylene glycol, 3,350 Daltons, Spectrum Chemicals, Gardena, CA) in 1M
Sodium Acetate (Spectrum, Gardena, CA) at pH=5.5 was made.
The polymer solution was added in a 2:1 volumetric ratio as follows: 750 pl of AS-oligonucleotides, 0.75 ml of poly-L-lysine.HBr, 3.0 ml of PEG/PVP, and a total volume of 4.50 ml.
synthesis facility at University of Pittsburgh (Pittsburgh, PA). The AS-oligonucleotides sequences are:
Seq ID 1: CD 40-AS: 5'C*AC* AG*C C*GA* GG*C* AA*A
GA*C* AC*C A*T*G C*AG* GG*C* A-3' Seq ID 2: CD80-AS: 5'-G*GG* AA*A G*CC* AG*G A*AT* CT*A
G*AG* CC*A A*TG G*A-3' Seq ID 3: CD86-AS: 5'-T*GG* GT*G C*TT* CC*G T*AA*
GT*T C*TG* GA*A C*AC* G*T*C-3' [00037] An aqueous solution of the oligonucleotide mixture was prepared by combining aliquots of three oligonucleotide solutions, each of which contained one type of oligonucleotide, to form a 10[mg/m1] solution of the three types of oligonucleotides. 10 [mg/ml] poly-L-lysine.HBr in diH20 (poly-L-lysine.HBr up to 50,000 by Bachem, King of Prussia, PA) was prepared. Poly-L-lysine.HBr was added to the oligonucleotides solution at a volumetric ratio of 1:1. The mixture was vortexed gently. A 25% polymer solution containing 12.5% PVP (polyvinyl pyrrolidone, 40,000 Daltons, Spectrum Chemicals, Gardena, CA) and 12.5% PEG (polyethylene glycol, 3,350 Daltons, Spectrum Chemicals, Gardena, CA) in 1M
Sodium Acetate (Spectrum, Gardena, CA) at pH=5.5 was made.
The polymer solution was added in a 2:1 volumetric ratio as follows: 750 pl of AS-oligonucleotides, 0.75 ml of poly-L-lysine.HBr, 3.0 ml of PEG/PVP, and a total volume of 4.50 ml.
[00038] The batch was incubated for 30 minutes at 70 C and then cooled to 23 C. Upon cooling, the solution became turbid and precipitation occurred. The suspension was then centrifuged, and the excess PEG/PVP was removed. The resulting pellet was washed by resuspending the pellet in deionized water, followed by centrifugation and removal of the supernatant. The washing process was repeated three times.
The aqueous suspension was frozen and lyophilized to form a dry powder of microspheres comprising oligonucleotide and poly-L-lysine.
The aqueous suspension was frozen and lyophilized to form a dry powder of microspheres comprising oligonucleotide and poly-L-lysine.
[00039] Fig. 6 presents a scanning electron micrograph (SEM) of the 1:1 poly-L-lysine:oligonucleotide ratio material.
Microspheres, 0.5-4 pm in size, with an average particle size of approximately 2.5 pm were fabricated. Precipitation of an unknown material was also observed. Additional studies by HPLC determined that the precipitation was comprised of residual PEG/PVP, mostly PVP.
Microspheres, 0.5-4 pm in size, with an average particle size of approximately 2.5 pm were fabricated. Precipitation of an unknown material was also observed. Additional studies by HPLC determined that the precipitation was comprised of residual PEG/PVP, mostly PVP.
[00040] AS-oligonucleotides targeted to the CD40, CD80 and CD86 primary transcripts were the AS-oligonucleotides sequences of Example 1. An aqueous solution of the oligonucleotide mixture was prepared by combining aliquots of the three oligonucleotide solutions, each of which contained one type of oligonucleotide, to form a 10[mg/m1] solution of the three types of oligonucleotides. A solution of oligonucleotide mixture was prepared. 5 [mg/ml] poly-L-ornithine.HBr in diH20 (poly-L-ornithine-HBr 11,900 (vis) by Sigma) was prepared. Poly-L-ornithine.HBr was added to the oligonucleotides solution. The mixtures were vortexed gently.
A 25% polymer solution containing 12.5% PVP (40,000 Daltons, Spectrum Chemicals, Gardena, CA) and 12.5% PEG (3,350 Daltons, Spectrum, Chemicals, Gardena, CA) in 0.1.M Sodium Acetate (Spectrum Chemicals, Gardena, CA) at pH=5.5 was made. The polymer solutions were added. Incubation and rinses followed as described in Example 1. 1.5 ml of the AS-oligonucleotides, 1.5 ml of the poly-L-ornithine-HBr, 3 ml of the PEG/PVP, and a total volume of 6.0 ml was prepared.
A 25% polymer solution containing 12.5% PVP (40,000 Daltons, Spectrum Chemicals, Gardena, CA) and 12.5% PEG (3,350 Daltons, Spectrum, Chemicals, Gardena, CA) in 0.1.M Sodium Acetate (Spectrum Chemicals, Gardena, CA) at pH=5.5 was made. The polymer solutions were added. Incubation and rinses followed as described in Example 1. 1.5 ml of the AS-oligonucleotides, 1.5 ml of the poly-L-ornithine-HBr, 3 ml of the PEG/PVP, and a total volume of 6.0 ml was prepared.
[00041] Fig. 7 presents an SEM of this 1:1 poly-L-ornithine:oligonucleotide ratio material. Microspheres, 0.2-8 pm in size, with an average particle size of approximately 2 pm were fabricated. Precipitation of an unknown material was also observed. Additional HPLC studies were able to prove that this precipitation was comprised of residual PEG/PVP, mostly PVP.
[00042] In vivo studies were conducted using the NOD mouse model of Type 1 diabetes mellitus. Type 1 diabetes is manifested by the autoimmune destruction of the pancreatic insulin-producing beta cells as illustrated in Fig. 1. AS-oligonucleotides were used in three applications in an attempt to interfere with the autoimmune destruction of beta cells.
The goal was to interfere with the dendritic cell function by targeting the primary transcripts of CD40, CD80 and CD86, which encode dendritric cell surface proteins required for T-cell activation. Dendritic cells with low levels of CD40, CD80 and CD86 are known to promote suppressive immune cell networks in vivo. These cascades can result in T-cell hyporesponsiveness to beta cells in vivo.
The goal was to interfere with the dendritic cell function by targeting the primary transcripts of CD40, CD80 and CD86, which encode dendritric cell surface proteins required for T-cell activation. Dendritic cells with low levels of CD40, CD80 and CD86 are known to promote suppressive immune cell networks in vivo. These cascades can result in T-cell hyporesponsiveness to beta cells in vivo.
[00043] In the first group of test animals, dendritic cells were propagated ex vivo from bone marrow progenitors of NOD
mice. Combinations of the three AS-oligonucleotides targeting the primary transcripts of CD40, CD80 and CD86 were added to the cells in tissue culture. After incubation, the AS-oligonucleotide transfected dendritic cells were injected into syngenetic recipients of 5 to 8 weeks of age (not yet diabetic). This is a known ex-vivo delivery approach.
mice. Combinations of the three AS-oligonucleotides targeting the primary transcripts of CD40, CD80 and CD86 were added to the cells in tissue culture. After incubation, the AS-oligonucleotide transfected dendritic cells were injected into syngenetic recipients of 5 to 8 weeks of age (not yet diabetic). This is a known ex-vivo delivery approach.
[00044] In parallel, AS-oligonucleotide microspheres were injected directly into other NOD mice of the same age. A
single injection was carried out on each thus-treated mouse. Another group of these NOD mice was not treated and served as a control.
single injection was carried out on each thus-treated mouse. Another group of these NOD mice was not treated and served as a control.
[00045] Fig. 8 shows that the control, untreated NOD mice all developed diabetes by age 23 weeks. The ex vivo AS-oligonucleotide transfected and re-infused dendritic cells group (AS-ODN DC) showed delayed development of diabetes, with 20% remaining "Diabetes Free", indicating glucose levels are maintained within a non-diabetic range. Of the microspheres in vivo-injected NOD mice, 71% remained "Diabetes Free" at 43 weeks.
[00046] It will be understood that the embodiments of the present invention which have been described are illustrative of some of the applications of the principles of the present invention. Numerous modifications may be made by those skilled in the art. Various features which are described herein can be used in any combination and are not limited to precise combinations which are specifically outlined herein. The scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
NOTE: For additional volumes please contact the Canadian Patent Office.
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
NOTE: For additional volumes please contact the Canadian Patent Office.
Claims (20)
1. A composition comprising microspheres, wherein said microspheres contain a first antisense oligonucleotide that targets CD40 primary transcript, a second antisense oligonucleotide that targets CD80 primary transcript, and a third antisense oligonucleotide that targets CD86 primary transcript, wherein each of said first, second and third oligonucleotides reduces or suppresses in vivo expression of CD40, CD80 and CD86 respectively, and wherein said oligonucleotides comprise between 30 weight percent and 100 weight percent of the microspheres, based on the total weight of the microspheres, said microspheres having an average particle size of not greater than 50 microns.
2. A composition comprising microspheres wherein the microspheres comprise oligonucleotides targeted to bind primary transcripts selected from the group consisting of CD40, CD80, and CD86 primary transcripts and combinations thereof, wherein the oligonucleotides reduce or suppress the expression of CD40, CD80 and/or CD86, and wherein the oligonucleotides comprise greater than 30 weight percent of the microspheres based on total weight of the microspheres.
3. The composition of claim 2, wherein the microspheres comprise a mixture of three different antisense oligonucleotides targeted to bind CD40, CD80, and CD86 primary transcripts.
4. The composition of any one of claims 1-3, wherein the microspheres further comprise a polycation.
5. The composition of claim 4, wherein the microspheres consist essentially of antisense oligonucleotides and the polycation.
6. The composition of any one of claims 1-5, wherein the microspheres are capable of being taken up by dendritic cells.
7. The composition of any one of claims 1-6, wherein the composition is an injectable composition suitable for in vivo delivery.
8. The composition of any one of claims 1-7, wherein the composition is suitable for subcutaneous administration.
9. An injectable composition for the treatment of type 1 diabetes comprising microspheres, said microspheres comprising a first antisense oligonucleotide that targets C940 primary transcript, a second antisense oligonucleotide that targets CD80 primary transcript, and a third antisense oligonucleotide that targets CD86 primary transcript, wherein each of said first, second and third antisense oligonucleotides reduces or suppresses the expression of CD40, CD80 and CD86 respectively, wherein said first, second and third antisense oligonucleotides comprise greater than 30% by weight of said microspheres.
10. The composition of any one of claims 2-9, wherein the microspheres have an average particle size less than 50 microns.
11. The composition of any one of claims 1-9, wherein the microspheres have a particle size of 0.2 microns to 8 microns.
12. The composition of any one of claims 1-9, wherein the microspheres have a particle size of 0.5 microns to 4 microns.
13. The composition of any one of claims 1-9, wherein the microspheres have an average particle size of 2 microns.
14. The composition of any one of claims 1-9, wherein the microspheres have an average particle size of 2.5 microns.
15. The composition of any one of claims 1-14, wherein the antisense oligonucleotides comprise greater than 60% by weight of the microspheres.
16. Use of the composition of any one of claims 1-15 for protecting beta cells of the pancreas of non-obese diabetic mice from autoimmune destruction, wherein the composition is suitable for subcutaneous injection.
17. Use of the composition of any one of claims 1-15 for delivering nucleic acids to an individual with type 1 diabetes, wherein the composition is suitable for a route of administration selected from the group consisting of intravenous, intramuscular, subcutaneous, topical, intradermal, intraperitoneal, oral, pulmonary, ocular, nasal, and rectal delivery.
18. Use of the composition of any one of claims 1-15 for protecting beta cells of the pancreas of an individual from autoimmune destruction, wherein the composition is suitable for subcutaneous injection.
19. Use of the composition of any one of claims 1-15 for protecting beta cells of the pancreas of an individual from autoimmune destruction and onset of type 1 diabetes, wherein the composition is suitable for subcutaneous injection.
20. The use of any one of claims 17-19, wherein the individual is a human.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57027304P | 2004-05-12 | 2004-05-12 | |
US60/570,273 | 2004-05-12 | ||
US62548304P | 2004-11-05 | 2004-11-05 | |
US60/625,483 | 2004-11-05 | ||
PCT/US2005/016689 WO2005112885A2 (en) | 2004-05-12 | 2005-05-12 | Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2566199A1 CA2566199A1 (en) | 2005-12-01 |
CA2566199C true CA2566199C (en) | 2013-10-22 |
Family
ID=35134160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2566199A Active CA2566199C (en) | 2004-05-12 | 2005-05-12 | Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes |
Country Status (11)
Country | Link |
---|---|
US (2) | US7884085B2 (en) |
EP (1) | EP1758558B1 (en) |
JP (2) | JP2007537288A (en) |
CN (1) | CN103432079A (en) |
AU (1) | AU2005244851B2 (en) |
CA (1) | CA2566199C (en) |
DK (1) | DK1758558T3 (en) |
ES (1) | ES2442115T3 (en) |
MX (1) | MXPA06012989A (en) |
PT (1) | PT1758558E (en) |
WO (1) | WO2005112885A2 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080026068A1 (en) * | 2001-08-16 | 2008-01-31 | Baxter Healthcare S.A. | Pulmonary delivery of spherical insulin microparticles |
AU2005244851B2 (en) * | 2004-05-12 | 2010-08-26 | Baxter Healthcare S.A. | Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1 |
ES2313350T3 (en) * | 2004-05-12 | 2009-03-01 | Baxter International Inc. | MICROSPHERAS OF NUCLEIC ACID, PRODUCTION AND SUPPLY OF THE SAME. |
US8728525B2 (en) * | 2004-05-12 | 2014-05-20 | Baxter International Inc. | Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
CA2604225A1 (en) * | 2005-04-27 | 2006-11-02 | Baxter International Inc. | Surface-modified microparticles and methods of forming and using the same |
WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
CA2648099C (en) | 2006-03-31 | 2012-05-29 | The Brigham And Women's Hospital, Inc | System for targeted delivery of therapeutic agents |
CA2652280C (en) | 2006-05-15 | 2014-01-28 | Massachusetts Institute Of Technology | Polymers for functional particles |
US20070281031A1 (en) * | 2006-06-01 | 2007-12-06 | Guohan Yang | Microparticles and methods for production thereof |
WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
AU2007281737B2 (en) * | 2006-08-04 | 2013-09-19 | Baxter Healthcare S.A. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
AU2013213750B2 (en) * | 2006-08-04 | 2013-09-26 | Baxter Healthcare S.A. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
MX2009003661A (en) * | 2006-10-06 | 2009-04-22 | Baxter Int | Microencapsules containing surface-modified microparticles and methods of forming and using the same. |
EP2134830A2 (en) | 2007-02-09 | 2009-12-23 | Massachusetts Institute of Technology | Oscillating cell culture bioreactor |
WO2008124639A2 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Poly (amino acid) targeting moieties |
ES2627292T3 (en) | 2007-10-12 | 2017-07-27 | Massachusetts Institute Of Technology | Vaccine Nanotechnology |
EP2982753B1 (en) * | 2008-04-18 | 2018-06-06 | Baxter International Inc. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
US20100047292A1 (en) * | 2008-08-20 | 2010-02-25 | Baxter International Inc. | Methods of processing microparticles and compositions produced thereby |
US8367427B2 (en) * | 2008-08-20 | 2013-02-05 | Baxter International Inc. | Methods of processing compositions containing microparticles |
US8323685B2 (en) * | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing compositions containing microparticles |
US8323615B2 (en) * | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing multi-phasic dispersions |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8591905B2 (en) * | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
JP6595469B2 (en) | 2013-11-18 | 2019-10-23 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapy |
WO2018024849A1 (en) * | 2016-08-03 | 2018-02-08 | Aalborg Universitet | ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS |
Family Cites Families (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US373337A (en) * | 1887-11-15 | Shaft-hanger | ||
DE2010115A1 (en) | 1970-03-04 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Process for the production of micro-granules |
JPS523342B2 (en) * | 1972-01-26 | 1977-01-27 | ||
US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
US4530840A (en) * | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
JPS60100516A (en) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | Preparation of sustained release microcapsule |
US4818542A (en) * | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
US4584894A (en) * | 1984-02-29 | 1986-04-29 | Borg-Warner Corporation | Transmission anti-clash and anti-rattle brake |
US5417986A (en) * | 1984-03-16 | 1995-05-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
EP0190833B1 (en) * | 1985-02-07 | 1991-03-27 | Takeda Chemical Industries, Ltd. | Method for producing microcapsule |
JP2551756B2 (en) * | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | Polyoxycarboxylic acid ester and method for producing the same |
US5102872A (en) * | 1985-09-20 | 1992-04-07 | Cetus Corporation | Controlled-release formulations of interleukin-2 |
GB8601100D0 (en) * | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
EP0248531A3 (en) | 1986-05-02 | 1988-09-28 | Southern Research Institute | Encapsulated nucleic acids |
ES2053549T3 (en) * | 1986-08-11 | 1994-08-01 | Innovata Biomed Ltd | A PROCESS FOR THE PREPARATION OF AN APPROPRIATE PHARMACEUTICAL FORMULATION FOR INHALATION. |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US4861627A (en) * | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
US4848542A (en) * | 1988-04-18 | 1989-07-18 | Richard Burnette | Package for retaining and mounting a mirror |
US5422120A (en) * | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
USRE39497E1 (en) | 1989-02-16 | 2007-02-27 | Nektar Therapeutics | Storage of materials |
DE69024953T3 (en) * | 1989-05-04 | 2005-01-27 | Southern Research Institute, Birmingham | encapsulation |
MY107937A (en) * | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
DK0528978T3 (en) * | 1990-05-16 | 2003-02-17 | Southern Res Inst | Microcapsules for regulated delivery and their use in stimulating nerve fiber growth |
JPH0436233A (en) * | 1990-05-29 | 1992-02-06 | Biomaterial Universe Kk | Sustained release preparation containing physiologically active substance and decomposable and absorbable in living body |
GB9016885D0 (en) * | 1990-08-01 | 1990-09-12 | Scras | Sustained release pharmaceutical compositions |
US5149543A (en) * | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
IT1243390B (en) * | 1990-11-22 | 1994-06-10 | Vectorpharma Int | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION. |
AU1442592A (en) * | 1991-02-20 | 1992-09-15 | Nova Pharmaceutical Corporation | Controlled release microparticulate delivery system for proteins |
US5330768A (en) * | 1991-07-05 | 1994-07-19 | Massachusetts Institute Of Technology | Controlled drug delivery using polymer/pluronic blends |
US6063910A (en) * | 1991-11-14 | 2000-05-16 | The Trustees Of Princeton University | Preparation of protein microparticles by supercritical fluid precipitation |
US5525519A (en) * | 1992-01-07 | 1996-06-11 | Middlesex Sciences, Inc. | Method for isolating biomolecules from a biological sample with linear polymers |
US5173454A (en) * | 1992-01-09 | 1992-12-22 | Corning Incorporated | Nanocrystalline materials |
US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
DE4211169C1 (en) | 1992-03-31 | 1993-06-03 | Klaus Kretzschmar | |
JP2651320B2 (en) * | 1992-07-16 | 1997-09-10 | 田辺製薬株式会社 | Method for producing sustained-release microsphere preparation |
JP3277342B2 (en) * | 1992-09-02 | 2002-04-22 | 武田薬品工業株式会社 | Manufacturing method of sustained release microcapsules |
EP0595030A3 (en) * | 1992-10-01 | 1995-06-07 | Tanabe Seiyaku Co | Sustained release multi-core microsphere preparation and method for producing the same. |
ATE195652T1 (en) * | 1992-12-02 | 2000-09-15 | Alkermes Inc | CONTROLLED RELEASE MICROSPHERES CONTAINING GROWTH HORMONE |
WO1994018947A1 (en) | 1993-02-16 | 1994-09-01 | Sharifa Karali | High purity protamine-dna complex and use of same |
JPH08507806A (en) | 1993-03-09 | 1996-08-20 | ミドルセツクス・サイエンシーズ・インコーポレーテツド | Polymer microparticles and preparation method |
US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5994314A (en) * | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
TW360548B (en) | 1993-04-08 | 1999-06-11 | Powderject Res Ltd | Products for therapeutic use |
US5543158A (en) * | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
DE69432867T2 (en) * | 1993-11-18 | 2004-04-22 | Sirtex Medical Ltd., Burswood | PREPARATION WITH CONTROLLED RELEASE |
DE69429820T3 (en) * | 1993-11-19 | 2013-02-28 | Alkermes Controlled Therapeutics, Inc. | PREPARATION OF BIODEGRADABLE MICROPARTICLES CONTAINING A BIOLOGICALLY ACTIVE SUBSTANCE |
US5650173A (en) * | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
US5858973A (en) * | 1994-02-23 | 1999-01-12 | The General Hospital Corporation | Transcription factor and uses therefor |
US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
JPH10503769A (en) | 1994-08-04 | 1998-04-07 | クアドラント ホールディングス ケンブリッジ リミテッド | Solid release system for controlled release of incorporated molecules and method of making same |
US5542920A (en) | 1994-09-12 | 1996-08-06 | Delab | Needle-less parenteral introduction device |
US6387399B1 (en) * | 1994-12-02 | 2002-05-14 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microencapsulated bioactive agents and method of making |
US5877021A (en) * | 1995-07-07 | 1999-03-02 | Ribozyme Pharmaceuticals, Inc. | B7-1 targeted ribozymes |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6265389B1 (en) * | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
SE505146C2 (en) * | 1995-10-19 | 1997-06-30 | Biogram Ab | Particles for delayed release |
US5665428A (en) | 1995-10-25 | 1997-09-09 | Macromed, Inc. | Preparation of peptide containing biodegradable microspheres by melt process |
US6270795B1 (en) * | 1995-11-09 | 2001-08-07 | Microbiological Research Authority | Method of making microencapsulated DNA for vaccination and gene therapy |
CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
US5958769A (en) | 1996-01-18 | 1999-09-28 | Fred Hutchinson Cancer Research Center | Compositions and methods for mediating cell cycle progression |
GB9607035D0 (en) | 1996-04-03 | 1996-06-05 | Andaris Ltd | Spray-dried microparticles as therapeutic vehicles |
GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
WO1998001162A2 (en) * | 1996-07-09 | 1998-01-15 | The Johns Hopkins University | Gene delivery system |
US6395302B1 (en) * | 1996-11-19 | 2002-05-28 | Octoplus B.V. | Method for the preparation of microspheres which contain colloidal systems |
US6319906B1 (en) | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US6077833A (en) * | 1996-12-31 | 2000-06-20 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US20020182258A1 (en) * | 1997-01-22 | 2002-12-05 | Zycos Inc., A Delaware Corporation | Microparticles for delivery of nucleic acid |
US5945126A (en) * | 1997-02-13 | 1999-08-31 | Oakwood Laboratories L.L.C. | Continuous microsphere process |
PT975334E (en) | 1997-04-17 | 2004-03-31 | Amgen Inc | BIODEGRADABLE MICROPARTICLES FOR THE SUSTAINED LIBERATION OF THERAPEUTIC PHARMACOS |
JP2001510151A (en) * | 1997-07-18 | 2001-07-31 | インファイムド,インク. | Biodegradable macromers for controlled release of bioactive substances |
EP1005442B1 (en) * | 1997-08-18 | 2003-04-02 | ExxonMobil Chemical Patents Inc. | Process to alkylate an aromatic with a dilute stream comprising propylene and ethylene |
US6042792A (en) | 1997-09-18 | 2000-03-28 | International Flavors & Fragrances Inc. | Apparatus for preparing a solid phase microparticulate composition |
US5989463A (en) * | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (en) * | 1997-10-23 | 2000-04-17 | Biogram Ab | Active substance encapsulation process in a biodegradable polymer |
DE69921773D1 (en) | 1998-01-16 | 2004-12-16 | Univ Johns Hopkins | ORAL ADMINISTRATION OF NUCLEIC ACID VACCINE THROUGH PARTICLE COMPLEXES |
US20040186071A1 (en) * | 1998-04-13 | 2004-09-23 | Bennett C. Frank | Antisense modulation of CD40 expression |
US6395253B2 (en) * | 1998-04-23 | 2002-05-28 | The Regents Of The University Of Michigan | Microspheres containing condensed polyanionic bioactive agents and methods for their production |
US6197584B1 (en) * | 1998-05-01 | 2001-03-06 | Isis Pharmaceuticals, Inc. | Antisense modulation of CD40 expression |
DE69931166T2 (en) * | 1998-08-14 | 2007-02-15 | Valentis Inc., Burlingame | CO-LYOPHILIZED COMPLEX COMPRISING A NUCLEIC ACID VECTOR AND A FORMULATION AGENCY |
US6270802B1 (en) * | 1998-10-28 | 2001-08-07 | Oakwood Laboratories L.L.C. | Method and apparatus for formulating microspheres and microcapsules |
US6194006B1 (en) * | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
DE60003151T2 (en) | 1999-01-13 | 2004-04-08 | Johns Hopkins University School Of Medicine | GENETIC IMMUNIZATION WITH SIMULTANEOUS ADMINISTRATION OF NUCLEIC ACIDS AND CYTOKINES |
GB9904627D0 (en) * | 1999-03-02 | 1999-04-21 | Danbiosyst Uk | Polymer compositions for polynucleotide delivery |
US6630169B1 (en) * | 1999-03-31 | 2003-10-07 | Nektar Therapeutics | Particulate delivery systems and methods of use |
WO2000062759A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Dry, mouldable drug formulation |
EP1046651A1 (en) * | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Composition and method for modulating dendritic cell-T interaction |
CA2369747A1 (en) | 1999-04-30 | 2000-11-09 | The Trustees Of The University Of Pennsylvania | Mutant human cd80 and compositions for and methods of making and using the same |
ATE334193T1 (en) | 1999-05-04 | 2006-08-15 | Genethor Gmbh | METHOD FOR REDUCING SPECIFIC IMMUNE REACTIONS |
EP1060741B1 (en) | 1999-06-14 | 2003-09-03 | Baxter International Inc. | Sustained release microspheres |
EP1194128A2 (en) | 1999-06-23 | 2002-04-10 | Sedum Laboratories | Ionically formulated biomolecule microcarriers |
US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
FR2809309B1 (en) * | 2000-05-23 | 2004-06-11 | Mainelab | EXTENDED RELEASE MICROSPHERES FOR INJECTION DELIVERY |
DK1283720T3 (en) | 2000-05-26 | 2007-08-13 | Symphogen As | Recombinant or purified polyclonal antibodies to treat allergy |
US6849259B2 (en) * | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
KR100392501B1 (en) * | 2000-06-28 | 2003-07-22 | 동국제약 주식회사 | Preparation Method for Sustained Release Microparticles by Multiple Emulsion Method and Micropartic les Thereof |
US6471995B1 (en) | 2000-09-27 | 2002-10-29 | Alkermes Controlled Therapeutics, Inc. Ii | Apparatus and method for preparing microparticles using liquid-liquid extraction |
AU1344102A (en) * | 2000-10-12 | 2002-04-22 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
SE518007C2 (en) | 2000-11-16 | 2002-08-13 | Bioglan Ab | Preparation of microparticles containing biologically active compounds useful in preparation for controlled release substance, comprises biodegradable polymer in an organic solvent |
EP1345968A2 (en) | 2000-12-28 | 2003-09-24 | Altus Biologics Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
EP1801123A3 (en) | 2000-12-28 | 2007-11-21 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
US6896905B2 (en) * | 2001-02-15 | 2005-05-24 | Rohm And Haas Company | Porous particles, their aqueous dispersions, and method of preparation |
GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
WO2003000014A2 (en) | 2001-06-21 | 2003-01-03 | Altus Biologics, Inc. | Spherical protein particles and methods of making and using them |
US20080026068A1 (en) | 2001-08-16 | 2008-01-31 | Baxter Healthcare S.A. | Pulmonary delivery of spherical insulin microparticles |
ES2307779T3 (en) | 2001-08-16 | 2008-12-01 | Baxter International Inc. | FORMULATIONS OF PROPELLENT-BASED MICROPARTICLES. |
GB0207440D0 (en) * | 2002-03-28 | 2002-05-08 | Ppl Therapeutics Scotland Ltd | Tolerogenic antigen-presenting cells |
EP1507874A4 (en) | 2002-05-28 | 2006-06-28 | Mirus Bio Corp | Compositions and processes for inhibiting gene expression using polynucleotides |
US6900998B2 (en) * | 2002-05-31 | 2005-05-31 | Midwest Research Institute | Variable-speed wind power system with improved energy capture via multilevel conversion |
CN1671741A (en) | 2002-06-21 | 2005-09-21 | 拜奥根Idec公司 | Buffered formulations for concentrating antibodies and methods of use thereof |
US20040014698A1 (en) * | 2002-07-18 | 2004-01-22 | Gonzalo Hortelano | Oral administration of therapeutic agent coupled to transporting agent |
EP1537846A1 (en) | 2002-09-11 | 2005-06-08 | Tanabe Seiyaku Co., Ltd. | Process for the production of microspheres and unit therefor |
US20060002862A1 (en) * | 2002-12-17 | 2006-01-05 | Medimmune Vaccines, Inc. | High pressure spray-dry of bioactive materials |
KR20050088175A (en) | 2002-12-17 | 2005-09-02 | 메드이뮨 백신즈 인코포레이티드 | High pressure spray-dry of bioactive materials |
WO2004060343A1 (en) | 2002-12-31 | 2004-07-22 | Nektar Therapeutics | Antibody-containing particles and compositions |
US20050158303A1 (en) * | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
JP4869064B2 (en) * | 2003-04-04 | 2012-02-01 | ジェネンテック, インコーポレイテッド | High concentration antibody and protein preparation |
ES2216707B1 (en) | 2003-04-08 | 2005-12-16 | Josep Maria Aran Perramon | OLIGORIBONUCLEOTIDIC SEQUENCE APPROVES TO A REGION OF THE CDNA THAT CODIFIES FOR THE HUMAN CD40 RECEPTOR AND DUPLEX OLIGORIBONUCLEOTIDES, VECTORS, PHARMACEUTICAL COMPOSITIONS AND CORRESPONDING USES. |
PL1639011T3 (en) * | 2003-06-30 | 2009-05-29 | Domantis Ltd | Pegylated single domain antibodies (dAb) |
WO2005008443A2 (en) | 2003-07-14 | 2005-01-27 | Environmental Security Corporation | Distributed sensor array for fluid contaminant monitoring |
US20050142205A1 (en) | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
MXPA06000720A (en) | 2003-07-18 | 2006-08-23 | Baxter Int | Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation. |
DE10355904A1 (en) | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Solid forms of anti-EGFR antibodies |
WO2005072527A2 (en) | 2004-01-23 | 2005-08-11 | Avi Biopharma, Inc. | Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
AU2005211890B2 (en) | 2004-02-12 | 2011-07-28 | Merck Patent Gmbh | Highly concentrated liquid formulations of anti-EGFR antibodies |
AU2005244851B2 (en) * | 2004-05-12 | 2010-08-26 | Baxter Healthcare S.A. | Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1 |
ES2313350T3 (en) | 2004-05-12 | 2009-03-01 | Baxter International Inc. | MICROSPHERAS OF NUCLEIC ACID, PRODUCTION AND SUPPLY OF THE SAME. |
CA2564791A1 (en) | 2004-06-14 | 2005-12-29 | Medimmune Vaccines, Inc. | High pressure spray-dry of bioactive materials |
US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
WO2006072527A1 (en) | 2005-01-05 | 2006-07-13 | Siemens Aktiengesellschaft | Head-up display for a motor vehicle |
JP4595112B2 (en) | 2005-02-14 | 2010-12-08 | 独立行政法人産業技術総合研究所 | Highly efficient separation or concentration of proteins |
ES2407468T3 (en) | 2005-04-18 | 2013-06-12 | Yeda Research And Development Company Limited | Stabilized anti-hepatitis B (HBV) antibody formulations |
RU2303833C2 (en) * | 2005-07-26 | 2007-07-27 | Самсунг Электро-Меканикс Ко., Лтд. | Lighting unit |
AU2006330858A1 (en) * | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
AU2007281737B2 (en) * | 2006-08-04 | 2013-09-19 | Baxter Healthcare S.A. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
US8002046B2 (en) * | 2008-10-10 | 2011-08-23 | Neeb Daniel A | Apparatus for reducing the incidence of tampering with automatic fire sprinkler assemblies |
-
2005
- 2005-05-12 AU AU2005244851A patent/AU2005244851B2/en not_active Ceased
- 2005-05-12 JP JP2007513370A patent/JP2007537288A/en active Pending
- 2005-05-12 PT PT57496747T patent/PT1758558E/en unknown
- 2005-05-12 ES ES05749674.7T patent/ES2442115T3/en active Active
- 2005-05-12 CA CA2566199A patent/CA2566199C/en active Active
- 2005-05-12 MX MXPA06012989A patent/MXPA06012989A/en active IP Right Grant
- 2005-05-12 DK DK05749674.7T patent/DK1758558T3/en active
- 2005-05-12 EP EP05749674.7A patent/EP1758558B1/en active Active
- 2005-05-12 WO PCT/US2005/016689 patent/WO2005112885A2/en active Application Filing
- 2005-05-12 US US11/127,360 patent/US7884085B2/en active Active
- 2005-05-12 CN CN2012105929369A patent/CN103432079A/en active Pending
-
2010
- 2010-06-24 US US12/822,774 patent/US9115357B2/en not_active Expired - Fee Related
-
2011
- 2011-09-13 JP JP2011199945A patent/JP5457414B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2005244851A1 (en) | 2005-12-01 |
PT1758558E (en) | 2013-12-05 |
JP2007537288A (en) | 2007-12-20 |
WO2005112885A2 (en) | 2005-12-01 |
CA2566199A1 (en) | 2005-12-01 |
JP5457414B2 (en) | 2014-04-02 |
US20060024240A1 (en) | 2006-02-02 |
CN103432079A (en) | 2013-12-11 |
DK1758558T3 (en) | 2014-01-20 |
US9115357B2 (en) | 2015-08-25 |
US7884085B2 (en) | 2011-02-08 |
ES2442115T3 (en) | 2014-02-10 |
AU2005244851B2 (en) | 2010-08-26 |
WO2005112885A3 (en) | 2006-02-09 |
MXPA06012989A (en) | 2007-06-12 |
EP1758558B1 (en) | 2013-10-16 |
JP2011256204A (en) | 2011-12-22 |
US20100260855A1 (en) | 2010-10-14 |
EP1758558A2 (en) | 2007-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2566199C (en) | Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes | |
US9339465B2 (en) | Nucleic acid microspheres, production and delivery thereof | |
JP2011256204A5 (en) | ||
JP5620946B2 (en) | Microsphere-based composition for preventing and / or reversing newly-onset autoimmune diabetes | |
CN1980641A (en) | Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |